Publikationen 2016

Azoitei A, Merseburger AS, Godau B, Hoda MR, Schmid E, Cronauer MV. C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. J Steroid Biochem Mol Biol. 2017 Feb;166:38-44. doi: 10.1016/j.jsbmb.2016.06.008.


Blasl F, Rösch WH, Koen M, Ardelean MA, Ebert AK. Cowper's syringocele: A rare differential diagnosis of infravesical obstruction in boys and young adults. J Pediatr Urol. 2016 Oct 8. pii: S1477-5131(16)30287-X. doi: 10.1016/j.jpurol.2016.08.023. [Epub ahead of print]


Bottke D, Bartkowiak D, Bolenz C, Wiegel T. [Radiotherapy in node-positive prostate cancer]. Urologe A. 2016 Mar;55(3):345-9. doi: 10.1007/s00120-016-0044-2. Review. German.


Breunig C, Zengerling F, Schnöller T, Schrader M, Jentzmik F. Recent Therapy of Organ-confined Testis Cancer. Aktuelle Urol. 2016 Apr;47(2):136-40. doi: 10.1055/s-0041-103446.


Busch J, Seidel C, Zengerling F. Male Extragonadal Germ Cell Tumors of the Adult. Oncol Res Treat. 2016;39(3):140-4. doi: 10.1159/000444271.


Cindric V.A., Reiche J., Hoischen C., Wohlmann A., Bratsch J., Friedrich K., Günes B., Cappallo-Obermann H., Kirchhoff C., Diekmann S., Günes C., Huber O. Characterization of SKAP/kinastrin isoforms: the N-terminus defines tissue specificity and Pontin binding. Hum Mol Genet. 2016 May 11.

Ebert AK. Editorial Comment. J Urol. 2016 Feb;195(2):470; discussion 470. doi: 10.1016/j.juro.2015.08.107. No abstract available.


Ebert AK, Lange T, Reutter H, Jenetzky E, Stein R, Boemers TM, Hirsch K, Rösch WH, Zwink N. Evaluation of sexual function in females with exstrophy-epispadias-complex: A survey of the multicenter German CURE-Net. J Pediatr Urol. 2016 Jul 13. pii: S1477-5131(16)30149-8. doi: 10.1016/j.jpurol.2016.04.052. [Epub ahead of print]


Hofbauer S, Kalogirou C, Roghmann F, Seitz AK, Vallo S, Wezel F, Worst T, Nawroth R. [Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics]. Urologe A. 2016 Sep 7. [Epub ahead of print] German


Jentzmik F, Azoitei A, Zengerling F, Damjanoski I, Cronauer MV. Androgen receptor aberrations in the era of abiraterone and enzalutamide. World J Urol. 2016 Mar;34(3):297-303. doi: 10.1007/s00345-015-1624-2.


Kertai MA, Rösch WH, Brandl R, Hirschfelder H, Zwink N, Ebert AK. Morphological and Functional Hip Long-Term Results after Exstrophy Repair. Eur J Pediatr Surg. 2016 Dec;26(6):508-513.


Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V. Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2016 Sep 23. pii: S0022-5347(16)31376-3. doi: 10.1016/j.juro.2016.09.078. [Epub ahead of print]


Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer. Anticancer Res. 2016 Oct;36(10):5205-5213.


Kriegmair MC, Mandel P, Moses A, Bolenz C, Michel MS, Pfalzgraf D. Zonal NephRo Score: external validation for predicting complications after open partial nephrectomy. World J Urol. 2016 Apr;34(4):545-51. doi: 10.1007/s00345-015-1648-7.


Kumar, M., Lechel, A., Günes C. Telomerase: The Devil Inside. Genes 7 (8), 2016 Jul 29;7(8).


Kunath F, Spek A, Jensen K, Zengerling F, Schmidt S. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance--protocol for a systematic review. Syst Rev. 2015 Dec 18;4:182. doi: 10.1186/s13643-015-0167-3.


Martini T, Aziz A, Roghmann F, Rink M, Chun FK, Fisch M, Trojan L, Hakenberg OW, Zastrow S, Wirth MP, Moersdorf J, Brookman-May S, Stief CG, Haferkamp A, Wagenlehner F, Hohenfellner M, Herrmann E, Lusuardi L, Grimm MO, Müller SC, Roigas J, Bastian PJ, Gierth M, Burger M, Pycha A, Seitz C, May M, Bolenz C. Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study. Urol Int. 2016;96(1):57-64. doi: 10.1159/000433606.


Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, Gierth M, Stief CG, Müller SC, Wagenlehner F, Roigas J, Hakenberg OW, Roghmann F, Nuhn P, Wirth M, Novotny V, Hadaschik B, Grimm MO, Schramek P, Haferkamp A, Colleselli D, Kloss B, Herrmann E, Fisch M, May M, Bolenz C. The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clin Genitourin Cancer. 2016 Sep 19. pii: S1558-7673(16)30276-2. doi: 10.1016/j.clgc.2016.09.003. [Epub ahead of print]


May M, Fritsche HM, Vetterlein MW, Bastian PJ, Gierth M, Nuhn P, Aziz A, Fisch M, Stief CG, Hohenfellner M, Wirth MP, Novotny V, Hakenberg OW, Noldus J, Gilfrich C, Bolenz C, Burger M, Brookman-May SD; PROMETRICS 2011 Research Group. Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. World J Urol. 2016 Jun 14. [Epub ahead of print]


May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, Hakenberg OW; PROMETRICS 2011 Research Group. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. Int Urol Nephrol. 2016 Nov 28. [Epub ahead of print]


Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, Shariat SF, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World J Urol. 2016 Aug;34(8):1155-61. doi: 10.1007/s00345-015-1737-7.

Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. 2016 Aug;94:314.e1-7. doi: 10.1016/j.urology.2016.05.030.


Schrader M, Zengerling F, Hakenberg OW, Protzel C. German national second-opinion network for testicular cancer and penile carcinoma : Two sources for evidence-based information. Urologe A. 2016 Sep;55(9):1192-8. doi: 10.1007/s00120-016-0201-7.


Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J Jr. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016 Sep 27;9(1):454.


von Hardenberg J, Schwartz M, Werner T, Fuxius S, Müller M, Bolenz C, Weiß C, Heinrich E. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer. Prostate. 2016 May;76(7):613-9. doi: 10.1002/pros.23152.


von Lowtzow C, Hofmann A, Zhang R, Marsch F, Ebert AK, Rösch W, Stein R, Boemers TM, Hirsch K, Marcelis C, Feitz WF, Brusco A, Migone N, Di Grazia M, Moebus S, Nöthen MM, Reutter H, Ludwig M, Draaken M. CNV analysis in 169 patients with bladder exstrophy-epispadias complex. BMC Med Genet. 2016 Apr 30;17(1):35. doi: 10.1186/s12881-016-0299-x.


Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS, Bolenz C. Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. Urol Int. 2016 Jan 19. [Epub ahead of print]


Zengerling F, Schmidt S. Antioxidants for male subfertility.  Urologe A. 2016 Jul;55(7):956-9. doi: 10.1007/s00120-016-0146-x.


Zengerling F, Azoitei A, Herweg A, Jentzmik F, Cronauer MV. Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7. World J Urol. 2016 May;34(5):633-9. doi: 10.1007/s00345-015-1674-5.

Publikationen 2015

Al Olama AA, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch GS, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokozorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lim HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Muir K, Vinuela A, Brown AA, PRACTICAL Consortium, COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative, Australian Prostate Cancer Bioresource, UK Genetic Prostate Cancer Study Collaborators, UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet 2015; (e-pub ahead of print).

Amin AO, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal D, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman C, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney K, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, Fitzgerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 2015; (e-pub ahead of print).

Böhm M, Maier C, Küfer R, Ropke A, Vogel W, Wieland I. Genetic Variants of DICE1/INTS6 in German Prostate Cancer Families with Linkage to 13q14. Urol Int 2015; (e-pub ahead of print).

Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Eur Urol 2015; (e-pub ahead of print).

Draaken M, Knapp M, Pennimpede T, Schmidt JM, Ebert AK, Rosch W, Stein R, Utsch B, Hirsch K, Boemers TM, Mangold E, Heilmann S, Ludwig KU, Jenetzky E, Zwink N, Moebus S, Herrmann BG, Mattheisen M, Nothen MM, Ludwig M, Reutter H. Genome-wide association study and meta-analysis identify ISL1 as genome-wide significant susceptibility gene for bladder exstrophy. PLoS Genet 2015; 11(3):e1005024.

Ebert AK, Adamczyk K. Epispadie und Harnröhrenduplikatur [Epispadias and urethral duplication]. Urologe A 2015; 54(5):634-640.

Egbers L, Luedeke M, Rinckleb A, Kolb S, Wright JL, Maier C, Neuhouser ML, Stanford JL. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. Am J Epidemiol 2015; 181(9):706-713.

Hautmann RE. Editorial Comment. J Urol 2015; (e-pub ahead of print).

Hautmann RE, Abol-Enein H, Lee CT, Mansson W, Mills RD, Penson DF, Skinner EC, Studer UE, Thueroff JW, Volkmer BG. Urinary diversion: how experts divert. Urology 2015; 85(1):233-238.

Knoll N, Wiedemann AU, Schrader M, Felber J, Burkert S, Daig I, Heckhausen J. Calibrating Independence Goals and Partner Support: Couples Adjust to Functional Limitations after Tumor Surgery. Appl Psychol Health Well Being 2015; (e-pub ahead of print).

Park W, Zwink N, Rösch WH, Schmiedeke E, Stein R, Schmidt D, Noeker M, Jenetzky E, Reutter H, Ebert AK. Sexual function in adult patients with classic bladder exstrophy: A multicenter study. J Pediatr Urol 2015; (e-pub ahead of print).

Reiter R, Brosch S, Ludeke M, Fischbein E, Rinckleb A, Haase S, Schwandt A, Pickhard A, Maier C, Hogel J, Vogel W. Do orofacial clefts represent different genetic entities? Cleft Palate Craniofac J 2015; 52(1):115-120.

Schmidt S, Kunath F, Kranz J, Zengerling F, Drager DL, Kröger N, Krabbe LM, Miernik A, Borgmann H, Spek A, Meerpohl J, Dahm P, Wullich B. Der Sprachbarriere zum Trotz [Overcoming the language barrier: UroEvidence translates Cochrane abstracts]. Urologe A 2015; 54(1):76-77.

Schnoeller TJ, Steinestel J, Steinestel K, Jentzmik F, Schrader AJ. Do preoperative serum C-reactive protein levels predict the definitive pathological stage in patients with clinically localized prostate cancer? Int Urol Nephrol 2015; 47(5):765-770.

Schnoeller TJ, Steinestel J, Zengerling F, Schrader AJ, Jentzmik F. Serum 17beta-estradiol fails as a marker in identification of aggressive tumour disease in patients with localized prostate cancer. World J Urol 2015; (e-pub ahead of print).

Schnöller TJ, Zengerling F, Hirning C, Jentzmik F. Sekundäre Prävention bei Patienten mit oberflächlichem Urothelkarzinom [Secondary prevention in patients with superficial urothelial carcinoma]. Urologe A 2015; (e-pub ahead of print).

Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin AO, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR, PRACTICAL Consortium, Australian Prostate Cancer Bioresource, Spurdle AB, Clements JA, Park JY, Batra J. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discov 2015; 5(4):368-379.

Steinestel J, Al Ghazal A, Arndt A, Schnoeller TJ, Schrader AJ, Moeller P, Steinestel K. The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma. BMC Cancer 2015; 15:220.

Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015; (e-pub ahead of print).

Weitere Originalarbeiten in Consortien:

Goulart LF, Bettella F, Sonderby IE, Schork AJ, Thompson WK, Mattingsdal M, Steen VM, Zuber V, Wang Y, Dale AM, PRACTICAL/ELLIPSE Consortium, Andreassen OA, Djurovic S. MicroRNAs enrichment in GWAS of complex human phenotypes. BMC Genomics 2015; 16(1):304.

Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TL, PRACTICAL Consortium, Wahlfors T, Schleutker J. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. Int J Cancer 2015; 136(10):2316-2327.

Murtola TJ, Wahlfors T, Haring A, Taari K, Stenman UH, Tammela TL, PRACTICAL Consortium, Schleutker J, Auvinen A. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. Eur Urol 2015; (e-pub ahead of print).

Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, Papatheodorou SI, Stanford JL, Albanes D, Virtamo J, Weinstein SJ, Diver WR, Gapstur SM, Stevens VL, Boeing H, Bueno-de-Mesquita HB, Barricarte GA, Kaaks R, Khaw KT, Krogh V, Overvad K, Riboli E, Trichopoulos D, Giovannucci E, Stampfer M, Haiman C, Henderson B, Le Marchand L, Gaziano JM, Hunter DJ, Koutros S, Yeager M, Hoover RN, PRACTICAL Consortium, Chanock SJ, Wacholder S, Key TJ, Tsilidis KK. A genome-wide pleiotropy scan for prostate cancer risk. Eur Urol 2015; 67(4):649-657. 1

Publikationen 2014

Al Ghazal A, Schnoeller TJ, Baechle C, Steinestel J, Jentzmik F, Steffens S, Hirning C, Schrader M, Schrader AJ. Capsulotomy for treatment of compartment syndrome in patients with post extracorporeal shock wave lithotripsy renal hematomas: safe and effective, but also advisable? Urol J 2014; 11(3):1569-1574.

Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Roder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokolorczyk D, Kluzniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G, Breast and Prostate Cancer Cohort Consortium (BPC3), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, COGS (Collaborative Oncological Gene-environment Study) Consortium, GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46(10):1103-1109.

Baumunk D, Strang CM, Kropf S, Schafer M, Schrader M, Weikert S, Cash H, Breckwoldt J, Miller K, Hachenberg T, Schostak M. Impact of thoracic epidural analgesia on blood loss in radical retropubic prostatectomy. Urol Int 2014; 93(2):193-201.

Breunig C, Schrader M, Schrader AJ, Zengerling F. Organerhaltende Hodentumortherapie [Organ-sparing therapy for testicular cancer]. Urologe A 2014; 53(9):1302-1309.

Bründl J, Zengerling F, Borgmann H, Syring I. Prostataeingriffe im Rahmen der urologischen Facharztweiterbildung [Prostate surgery within residency programs in urology]. Urologe A 2014; 53(3):379-381.

Cronauer MV, Schrader MG, Schrader AJ. Re: J.A. Witjes. A Case of Abiraterone Acetate Withdrawal (Eur Urol 2013;64:517-518). Eur Urol 2014; 65(1):e10-e11.

Draaken M, Baudisch F, Timmermann B, Kuhl H, Kerick M, Proske J, Wittler L, Pennimpede T, Ebert AK, Rosch W, Stein R, Bartels E, von Lowtzow C, Boemers TM, Herms S, Gearhart JP, Lakshmanan Y, Kockum CC, Holmdahl G, Lackgren G, Nordenskjold A, Boyadjiev SA, Herrmann BG, Nothen MM, Ludwig M, Reutter H. Classic bladder exstrophy: Frequent 22q11.21 duplications and definition of a 414 kb phenocritical region. Birth Defects Res A Clin Mol Teratol 2014; 100(6):512-517.

Ebert AK, Rösch WH. Editorial Comment. J Urol 2014; 191(1):197-198.

Engel O, de Petriconi R, Volkmer BG, Gust KM, Mani J, Haferkamp A, Hautmann RE, Bartsch G. The feasibility of ureteral tissue engineering using autologous veins: an orthotopic animal model with long term results. J Negat Results Biomed 2014; 13(1):17.

Hautmann RE. Editorial comment. Urology 2014; 84(4):813.

Hautmann RE, Herr HW, Pruthi RS, Aron M. Robotic radical cystectomy-is the diversion the achilles' heel? J Urol 2014; 192(6):1601-1603.

Hegele A, Skrobek L, Schrader AJ. ASCO, ESMO, AUA, EAU, DGU - Update Uroonkologie - Was war klinisch relevant auf den Kongressen 2013? [Update Urooncology: News with clinical relevance from major scientific meetings 2013]. Aktuelle Urol 2014; 45(1):21-32.

Jentzmik F, Schnoeller TJ, Cronauer MV, Steinestel J, Steffens S, Zengerling F, Al Ghazal A, Schrader MG, Steinestel K, Schrader AJ. Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage. Int J Urol 2014; 21(10):980-986.

Knoll N, Wiedemann AU, Schultze M, Schrader M, Heckhausen J. Prostate cancer patients gradually advance goals for rehabilitation after radical prostatectomy: applying a lines-of-defense model to rehabilitation. Psychol Aging 2014; 29(4):787-792.

Kranz J, Kunath F, Borgmann H, Dräger DL, Krabbe LM, Kröger N, Otto W, Spek A, Zengerling F, Wullich B, Miernik A. „UroEvidence" – Zentrum für evidenzbasierte Medizin der DGU ["UroEvidence" - Centre for knowledge translation of the DGU (German Society of Urology). Summarizing, analysing and making current knowledge available]. Urologe A 2014; 53(1):83-86.

Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, Shariat SF. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int 2014; 113(1):11-23.

Magheli A, Busch J, Leva N, Schrader M, Deger S, Miller K, Lein M. Comparison of surgical technique (open vs. laparoscopic) on pathological and long term functional outcomes following radical prostatectomy. BMC Urol 2014; 14:18.

Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Prostate 2014; 74(14):1444-1451.

Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014; 83(4):863-867.

Reutter H, Draaken M, Pennimpede T, Wittler L, Brockschmidt FF, Ebert AK, Bartels E, Rosch W, Boemers TM, Hirsch K, Schmiedeke E, Meesters C, Becker T, Stein R, Utsch B, Mangold E, Nordenskjold A, Barker G, Kockum CC, Zwink N, Holmdahl G, Lackgren G, Jenetzky E, Feitz WF, Marcelis C, Wijers CH, Van Rooij IA, Gearhart JP, Herrmann BG, Ludwig M, Boyadjiev SA, Nothen MM, Mattheisen M. Genome-wide association study and mouse expression data identify a highly conserved 32 kb intergenic region between WNT3 and WNT9b as possible susceptibility locus for isolated classic exstrophy of the bladder. Hum Mol Genet 2014; 23(20):5536-5544.

Roos FC, Steffens S, Junker K, Janssen M, Becker F, Wegener G, Brenner W, Steinestel J, Schnoeller TJ, Schrader M, Hofmann R, Thuroff JW, Kuczyk MA, Wunderlich H, Siemer S, Hartmann A, Stöckle M, Schrader AJ. Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer 2014; 14:372.

Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 2014; 111(11):2103-2113.

Saunders EJ, Dadaev T, Leongamornlert DA, Jugurnauth-Little S, Tymrakiewicz M, Wiklund F, Al Olama AA, Benlloch S, Neal DE, Hamdy FC, Donovan JL, Giles GG, Severi G, Gronberg H, Aly M, Haiman CA, Schumacher F, Henderson BE, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Nordestgaard BG, Canzian F, Campa D, Riboli E, Key TJ, Travis RC, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Clements JA, Teixeira MR, Xu J, Mikropoulos C, Goh C, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative, UK Genetic Prostate Cancer Study Collaborators, UK ProtecT Study Collaborators, PRACTICAL Consortium, Easton DF, Muir K, Eeles RA, Kote-Jarai Z. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet 2014; 10(2):e1004129.

Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV. Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone. Eur Urol 2014; 65(1):30-36.

Schrader AJ, Schrader MG, Cronauer MV. Re: Christoph A. von Klot, Markus A. Kuczyk, Axel S. Merseburger. No Androgen Withdrawal Syndrome for Enzalutamide: A Report of Disease Dynamics in the Postchemotherapy Setting (Eur Urol 65:258-259): Enzalutamide Withdrawal Syndrome: Fact or Fiction?http://www.ncbi.nlm.nih.gov/pubmed/24210913 Eur Urol 2014; 65(2):e22-23. 

Schrader AJ, Seseke S, Keil C, Herrmann E, Goebell PJ, Weikert S, Steffens S, Bergmann L, Roigas J, Steiner T. Temsirolimus in Daily Use: Results of a Prospective Multicentre Noninterventional Study of Patients with Metastatic Kidney Cancer. Eur Urol 2013;

Steffens S, Janssen M, Roos FC, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thuroff JW, Hofmann R, Stockle M, Schrader M, Hartmann A, Hasenfus A, Kuczyk MA, Junker K, Schrader AJ. The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma. Hum Pathol 2014; 45(12):2411-2416.

Steffens S, Junker K, Roos FC, Janssen M, Becker F, Henn D, Wegener G, Siemer S, Hofmann R, Schrader M, Stöckle M, Thüroff JW, Hartmann A, Kuczyk MA, Schrader AJ. Small renal cell carcinomas - How dangerous are they really? Results of a large multicenter study. Eur J Cancer 2013;

Steffens S, Roos FC, Janssen M, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thuroff JW, Hofmann R, Stockle M, Schrader M, Hartmann A, Junker K, Kuczyk MA, Schrader AJ. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch 2014; 465(4):439-444.

Steffens S, Schrader AJ, Lehmann R, Eggers H, Ising S, Pfister D, Riechert-Mühe N, Leitenberger A, Heidenreich A, Thon W, Merseburger AS, Kuczyk MA. Blickdiagnose bei der transurethralen Resektion von Harnblasentumoren [Visual diagnosis while performing transurethral resection of bladder tumors : Power or myth?]. Urologe A 2014; 53(11):1639-1643.

Steinestel J, Schrader AJ, Luedeke M. Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med 2014; 371(23):2234.

Steinestel K, Brüderlein S, Lennerz JK, Steinestel J, Kraft K, Propper C, Meineke V, Möller P. Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Mol Cancer 2014; 13:145.

Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 2014; 3:17.

Streicher W, Luedeke M, Azoitei A, Zengerling F, Herweg A, Genze F, Schrader MG, Schrader AJ, Cronauer MV. Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARDeltaLBD-signalling in human prostate cancer cells. PLoS One 2014; 9(6):e98566.

Teerlink CC, Thibodeau SN, McDonnell SK, Schaid DJ, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Fitzgerald LM, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Wahlfors T, Tammela T, Schleutker J, Wiklund F, Gronberg H, Emanuelsson M, Carpten J, Bailey-Wilson J, Whittemore AS, Oakley-Girvan I, Hsieh CL, Catalona WJ, Zheng SL, Jin G, Lu L, Xu J, Camp NJ, Cannon-Albright LA. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet 2013; (e-pub ahead of print)

Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, Rubin MA, Scherr DS, Shariat SF, Robinson BD. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. J Urol 2013; (e-pub ahead of print)

Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 2014; 40(1):121-127.

Zengerling F, Hartmann M, Heidenreich A, Krege S, Albers P, Karl A, Weissbach L, Wagner W, Bedke J, Retz M, Schmelz HU, Kliesch S, Kuczyk M, Winter E, Pottek T, Dieckmann KP, Schrader AJ, Schrader M. German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice. Oncol Rep 2014; 31(6):2477-2481.

Zengerling F, Krege S, Schrader AJ, Schrader M. Nationales Zweitmeinungsnetzwerk Hodentumoren - ein System zum Evidenztransfer! [National second opinion network for testicular cancer patients - transferring guidelines into practice!]. Aktuelle Urol 2014; 45(6):454-456.

Zengerling F, Müller J, Krege S, Schrader M. Diagnostik und Therapie seminomatöser Hodentumoren [Diagnostics and treatment of seminomatous germ cell tumors]. Urologe A 2014; 53(4):563-574.

Publikationen 2013

Al Ghazal A, Steffens S, Steinestel J, Lehmann R, Schnoeller TJ, Schulte-Hostede A, Wegener G, Jentzmik F, Schrader M, Kuczyk MA, Schrader AJ. Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer. BMC Urol 2013; 13(1):53.

 

Amin AO, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dork T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Roder MA, Frikke-Schmidt R, Bojesen SE, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2013; 22(2):408-415.

 

Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M. Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charite Berlin. BMC Med Inform Decis Mak 2013; 13:83.

 

Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Classen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germa L, Jr., Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2013; 24(4):878-888.

 

Blacha C, Schmid MM, Gahr M, Freudenmann RW, Plener PL, Finter F, Connemann BJ, Schönfeldt-Lecuona C. Self-inflicted testicular amputation in first lysergic acid diethylamide use. J Addict Med 2013; 7(1):83-84.

 

Damjanoski I, Müller J, Schnöller TJ, Küfer R, Rinnab L. Histopathologische Befundberichte von Prostatastanzbiopsien [Histopathology reports of findings of prostate needle biopsies : Indiviaual treatment.]. Urologe A 2013; 52(2):226-239.

 

Ebert AK, Rösch W. Paediatric urology: Is osteotomy necessary for primary exstrophy closure? Nat Rev Urol 2013; 10(11):625-626.

 

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, Kote-Jarai Z, Easton DF. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45(4):385-391.

 

Eggers H, Kuczyk MA, Schrader AJ, Steffens S. Der Einfluss von Adipositas auf urologische Tumorerkrankungen [Influence of obesity on urological malignancies]. Urologe A 2013; 52(9):1270-1275.

 

Eggers H, Seidel C, Schrader AJ, Lehmann R, Wegener G, Kuczyk MA, Steffens S. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Med Oncol 2013; 30(4):705.

 

Hautmann RE, Abol-Enein H, Davidsson T, Gudjonsson S, Hautmann SH, Holm HV, Lee CT, Liedberg F, Madersbacher S, Manoharan M, Mansson W, Mills RD, Penson DF, Skinner EC, Stein R, Studer UE, Thueroff JW, Turner WH, Volkmer BG, Xu A. ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary Diversion. Eur Urol 2013; 63(1):67-80.

 

Köhler A, Eggers H, Kuczyk MA, Schrader AJ, Steffens S. Stellenwert des Serum-CRP-Wertes zur Einschätzung von Prognose und therapeutischem Ansprechen urologischer Malignome [Utility of the Serum CRP Value for Assessing the Prognosis and Therapeutic Response of Urological Malignancies]. Aktuelle Urol 2013; 44(6):452-455. 

Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russell R, Dunning AM, Luccarini C, Dennis J, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC, Easton DF, Eeles RA. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013; 22(12):2520-2528.

Mueller J, Schrader AJ, Schrader M, Schnoeller T, Jentzmik F. Management of muscle-invasive bladder cancer. Minerva Urol Nefrol 2013; 65(4):235-248.

Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urol Oncol 2013; 31(8):1716-1724.

 

Schnoeller T, Jentzmik F, Rinnab L, Cronauer MV, Damjanoski I, Zengerling F, Ghazal AA, Schrader M, Schrader AJ. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol 2013; 31(2):253-259.

 

Schnoeller TJ, de Petriconi R, Hefty R, Jentzmik F, Al Ghazal A, Steinestel J, Mueller J, Zengerling F, Schrader M, Schrader AJ. Anwendung von Surgisis® zur Optimierung und Vereinfachung der Nierenteilresektion bei größeren renalen Neoplasmen [The use of Surgisis(R) optimizes and simplifies partial nephrectomy for large renal tumors.]. Urologe A 2013; 52(2):246-251. .

 

Schrader AJ, Schrader MG, Cronauer MV. Words of wisdom. Re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Eur Urol 2013; 64(1):169-170.

Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013; 45(12):1428-1430.

Steffens S, Al Ghazal A, Steinestel J, Lehmann R, Wegener G, Schnoeller TJ, Cronauer MV, Jentzmik F, Schrader M, Kuczyk MA, Schrader AJ. High CRP values predict poor survival in patients with penile cancer. BMC Cancer 2013; 13:223.

 

Steffens S, Ringe KI, Schroeer K, Lehmann R, Rustemeier J, Wegener G, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ. Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study. Int J Urol 2013; 20(6):585-592.

 

Stein B, Schrader AJ, Wegener G, Seidel C, Kuczyk MA, Steffens S. Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer 2013; 13:101.

 

Steinestel J, Cronauer MV, Müller J, Al Ghazal A, Skowronek P, Arndt A, Kraft K, Schrader M, Schrader AJ, Steinestel K. Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PLoS One 2013; 8(5):e65189.

 

Steinestel K, Gläsle F, Brüderlein S, Steinestel J, Pröpper C, Möller P. Abelson interactor 1 (Abi1) im kolorektalen Karzinom: Von der synaptischen Plastizität zur Tumorzellmigration [Abelson interactor 1 (Abi1) in colorectal cancer: From synaptic plasticity to tumor cell migration]. Pathologe 2013; 34(Suppl 2):189-194.

 

Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, McDonnell SK, Derycke MS, Cancel-Tassin G, Cussenot O, Wiklund F, Gronberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, Foulkes WD, Hamel N, Mahle L, Moller P, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2013; 132(1):5-14.

 

Zengerling F, Müller J, Schrader AJ, Schrader M. Seminom klinisches Stadium I - Neuer Therapiestandard Surveillance? [Clinical stage I seminoma - Is surveillance a new therapy standard?]. Urologe A 2013; 52(9):1265-1269.

 

Zengerling F, Schrader AJ, Mohr A, Schrader M. Nationales Zweitmeinungsnetzwerk testikuläre Keimzelltumoren [National second-opinion network for testicular cancer patients. Results of a user survey]. Urologe A 2013; 52(9):1290-1295.

 

Weitere Originalarbeiten in Consortien:
Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, PRACTICAL Consortium, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013; 4:1628.

 

Yu OH, Foulkes WD, Dastani Z, Martin RM, Eeles R, PRACTICAL Consortium, CRUK GWAS Investigators, Richards JB. An assessment of the shared allelic architecture between type II diabetes and prostate cancer. Cancer Epidemiol Biomarkers Prev 2013; 22(8):1473-1475.

Publikationen

gepunktete hellblaue Linie 176px breit
gepunktete blaue Linie 1000px breit